Biologics Market Size to Expand at Highest Revenue US$ 456.83 Billion with Growth Rate at 7.6% CAGR by 2027

Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).

𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

The global biologics market is expected to witness significant growth during the forecast period, owing to increasing product launches by key players such as Pfizer, Merck and Co., and GlaxoSmithKline (GSK). For instance, Pfizer has a robust pipeline for vaccines, biosimilars, biologics, and small molecules for 2019. The company has around 100 products in trial phase with 35 in phase 1, 28 in phase 2, 26 in phase 3, and 11 in the process of registration. The most recent one was for Pfizer’s DAURISMO (glasdegib), which received the U.S. Food and Drug Administration (FDA) approval in November 2018. It was indicated for adult patients with newly-diagnosed acute myeloid leukemia for who intensive chemotherapy is not a viable option.

Moreover, the global biologics market is rapidly growing, owing to increasing number of U.S. FDA approvals for new biologics medicines indicated for the treatment of rare disease. For instance, in December 2017, GlaxoSmithKline (GSK) received the U.S. FDA approval for its biologic ‘Nucala’, which is indicated for the treatment of rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA). Moreover, the U.S. FDA approved around 46 more biologics in 2017.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝟑𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/insight/buy-now/2663

𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

Among regions, North America holds dominant position in the global biologics market. This is owing to high presence of major biopharmaceutical and pharmaceutical companies in the U.S. including Biogen Idec, Eli Lily and Compaby, AbbVie, GlaxoSmithKline, Amgen, Novartis, Johnson and Johnson, Sanofi, and Pfizer. Increasing product approvals from regulatory authorities is expected to boost the biologics market in North America. For instance, in 2018, the U.S. FDA’s Center for Drug Evaluation and Research approved 59 novel drugs and biologics and were launched in the U.S.

Furthermore, Asia Pacific is expected to exhibit significant growth in the global biologics market, owing to increasing production of biosimilar products of biologics. A biosimilar is typically a biologic medical product, which is almost an identical copy of the original product that is manufactured by a different company. For instance, Biocon Ltd., an Indian biopharmaceutical company, launched two biosimilars namely CANMAb (trastuzumad) and Krabeva (bevacuzumab) in India in 2017 and 2017. These biosimilars were indicated for the treatment of several types of cancer.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Key players operating in the global biologics market include 𝗔𝗯𝗯𝗩𝗶𝗲, 𝗔𝗺𝗴𝗲𝗻, 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮, 𝗕𝗶𝗼𝗴𝗲𝗻 𝗜𝗱𝗲𝗰, 𝗕𝗿𝗶𝘀𝘁𝗼𝗹-𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯, 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝗮𝗻𝘆, 𝗚𝗹𝗮𝘅𝗼𝗦𝗺𝗶𝘁𝗵𝗞𝗹𝗶𝗻𝗲, 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 𝗮𝗻𝗱 𝗝𝗼𝗵𝗻𝘀𝗼𝗻, 𝗠𝗲𝗿𝗰𝗸 𝗮𝗻𝗱 𝗖𝗼., 𝗠𝗲𝗿𝗰𝗸 𝗞𝗚𝗮𝗔, 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀, 𝗣𝗳𝗶𝘇𝗲𝗿, 𝗙. 𝗛𝗼𝗳𝗳𝗺𝗮𝗻𝗻-𝗟𝗮 𝗥𝗼𝗰𝗵𝗲 𝗟𝘁𝗱, 𝗮𝗻𝗱 𝗦𝗮𝗻𝗼𝗳𝗶.

𝐓𝐨 𝐆𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/2663

Global Biologics Market: Taxonomy

𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐛𝐚𝐬𝐢𝐬 𝐨𝐟 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐲𝐩𝐞, 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧, 𝐞𝐧𝐝 𝐮𝐬𝐞𝐫, 𝐚𝐧𝐝 𝐫𝐞𝐠𝐢𝐨𝐧.

By Product Type

• Monoclonal Antibodies
• Vaccines
• Recombinant Hormones/Proteins
• Cell Therapy
• Gene Therapy

By Application

• Oncology
• Infectious Diseases
• Immunology
• Autoimmune Diseases
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝟑𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/insight/buy-now/2663

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.